Hair loss news – Hair loss and how to prevent it

Trial of Ritlecitinib in Alopecia Areata

Trial of Ritlecitinib in Alopecia Areata

/in /by

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2

Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 per cent scalp hair loss after six months of treatment versus placebo.

European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 per cent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.

A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 per cent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo.

This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups.

The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles).

There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

Full results from this study will be submitted for future scientific publication and presentation. These data, together with data that will become available from ALLEGRO-LT, will form the basis for planned future regulatory filings.

Ritlecitinib is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In laboratory studies, ritlecitinib has been shown to block the activity of signalling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata.3

Ritlecitinib, which was granted Breakthrough Therapy designation from the U.S. FDA for the treatment of alopecia areata in September 2018, is also being evaluated for vitiligo, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

About the Phase 2b/3 ALLEGRO Trial

This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718). Patients included in the study had 50 per cent or more hair loss of the scalp, including patients with alopecia totalis (complete scalp hair loss) and Alopecia Universalis (complete scalp, face and body hair loss), and were experiencing a current episode of alopecia areata that had lasted between six months and ten years. Patients were randomized to receive ritlecitinib 50 mg or 30 mg (with or without one month of initial treatment with once-daily ritlecitinib 200 mg), ritlecitinib 10 mg or placebo.

The primary endpoint was the proportion of patients with scalp hair regrowth in response to ritlecitinib treatment, based on an absolute SALT Score ≤20 at Week 24. SALT is a tool that measures the amount of scalp hair loss. The tool divides the scalp into standard regions, and each region contributes to the total SALT score, which ranges from 0 to 100. A SALT score of 0 corresponds to no scalp hair loss, while a SALT score of 100 corresponds to a total lack of hair on the scalp.4

More information about the Phase 2b/3 ALLEGRO trial can be found at https://www.clinicaltrials.gov under the identifier NCT03732807.

About Alopecia Areata

Alopecia areata is an autoimmune disease characterized by patchy hair loss, almost always involving the scalp, but sometimes also involving the face (eyebrows, eyelashes, beard), the whole scalp or the whole body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out.1,2 The mean age of onset is between 25 and 35 years, but it can also impact older adults, children and adolescents, and is seen in both sexes and all ethnicities.1,2 Alopecia areata is associated with poor health-related quality of life for many patients, who may suffer from serious psychological consequences, including depression and anxiety.1

1 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology. 2015;8:397-403. doi:10.2147/CCID.S53985.

2 Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature reviews Disease primers. 2017;3:17011. doi:10.1038/nrdp.2017.11.

3 King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20:S0190-9622(21)00601-0. doi: 10.1016/j.jaad.2021.03.050.

4 Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Source

Recent Posts

Hair Transplant Before and After Photos

Clinic for Female Hair Transplant

/in /by

Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women

Silicon Valley Hair Institute, a highly-rated Bay Area hair transplantation clinic is proud to announce a new page focused on women’s hair loss treatments. The newly released before-and-after photos of women’s hair restoration including hairline treatments are available to review.

“Women’s hair loss is not the same as men’s. We believe a page centred around their experiences may be helpful to the community,” explained Miguel Canales, MD. “Photos show our female patients before and after their hair loss treatments so the public can see the results for themselves.”

The public can review the new “before and after” page focused on female hairline restoration. Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women Thinner, more brittle hair could be signs of female hair loss instead of a typical “receding” hairline found in men. A top clinic focused on female hair transplant support in the Bay Area can help residents review options.

Treatments for women can include the following: robotic hair transplant surgery, light therapy, and supplement protocols. The clinic serves both women and men prepared to address hair loss issues. Bay Area residents can review the clinic’s “before and after” page for men at https://siliconvalleyhairinstitute.com/before-after/.

Those looking for skincare issues are encouraged to visit the sister website at https://svaestheticderm.com/.

FEMALE HAIR TRANSPLANT CLINIC IN BAY AREA AIMS THE SPOTLIGHT ON WOMEN’S HAIR LOSS

Here is the background on this release. Baldness may be a common issue for men living in the San Francisco area. However, women struggling with thinning hair confront unique problems. Confusion over how to manage the problem and a loss of confidence could result from thinning hair in women.

For these reasons, Silicon Valley Hair Institute announces a new women-centred page of “before and after” examples of hair loss treatments, especially for hair line issues. Female hair loss can present as a widening part and all-over thinner hair. Treatments may include hair transplantation, nutritional protocols, and micro-pigmentation. A state-of-the-art clinic helps focus the spotlight on female hair transplant services in the Bay Area.

ABOUT THE SILICON VALLEY HAIR INSTITUTE

Silicon Valley Hair Institute under the leadership of top-rated California hair transplant surgeon Dr Miguel Canales – is one of the best robotic hair transplant clinics in the San Francisco Bay Area.

Dr Canales provides both the FUT (Follicular Unit Transplant and FUE hair transplant (Follicular Unit Extraction procedures.

Dr Canales is a top-rated hair transplant specialist for Bay Area residents. The Silicon Valley Hair Institute specializes in hair loss and hair restoration needs in San Francisco, San Jose, and the Silicon Valley Peninsula (Sunnyvale, Mountain View, Palo Alto, Los Altos, Menlo-Atherton, Redwood City, and beyond.). Dr Canales also specializes in aesthetic hair restoration for females seeking eyebrow transplantation or hairline advancements.

Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women

Source

Recent Posts

Hair Loss Men and Women

Hair Loss Men and Women

/in /by

Hair Loss Men and Women Comprehensive Study

Hair loss in men and women experience androgenetic alopecia with equal frequency, although it may be camouflaged better in women. The other terms for androgenetic alopecia such as “male pattern balding” and “female pattern hair loss”.

According to the American Hair Loss Association, approximately two-thirds of men will have lost a little hair by the age of thirty-five and approximately 85% of men and women will have experienced hair thinning or have lost a significant amount of hair by the age of fifty.

Growth Drivers

  • Increasing Hair Loss Problems
  • Increased geriatric population in the developed economies
  • Rising Disposable Income

Market Trends

  • Rising consumer concern pertaining to receding hairlines

Roadblocks

  • Increasing Laser Hair Treatment and OTC Drugs

Opportunities

  • Rising consumer concern pertaining to receding hairlines

Challenges

  • Lack of proper treatment and the shortage of R&D in emerging economies

Competitive Landscape:

Some of the key players profiled in the report are Procter & Gamble (United States), L’Oreal (France), Unilever (United Kingdom), Taisho (Japan), Henkel (Germany), Merck & Co. (United States), Shiseido (Japan), Johnson & Johnson Consumer Inc. (United States), Rohto (Japan), Lifes2Good (Ireland), Gerolymatos International (Greece) and Toppik Inc. (United States).

Additionally, the following companies can also be profiled that are part of our coverage like Nanogen (United Kingdom), Oxford BioLabs Ltd. (United Kingdom) and Ultrax Labs (United States).

AMA Research sees the United States and United Kingdom Players retain a maximum share of the Global Hair Loss Men and Women market by 2026. Considering Market by End-Use, the sub-segment i.e. Dermatology clinics will boost the Hair Loss Men and Women market.

Considering Market by Sales Channel, the sub-segment i.e. Prescription will boost the Hair Loss Men and Women market.

What Can be Explored with the Hair Loss Men and Women Market Study

 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hair Loss Men and Women Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hair Loss Men and Women
 Understand the Competitive Scenario
– Track Right Markets
– Identify the Right Verticals

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hair Loss Men and Women market.

In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hair Loss Men and Women market.

In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.

Finally, the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.

This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.

Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Hair Loss Men and Women Comprehensive Study

Source

Recent Posts

Alopecia Treatment

Global and Japan Alopecia Market

/in /by

Global and Japan Alopecia (Hair Loss Treatment) Market Insights, Forecast to 2027

This insightful report has a lot to give on  Alopecia (Hair Loss Treatment) market covering wide geographic scope around the world. The  Alopecia (Hair Loss Treatment) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

The report is focused on gaining various market trends, dynamics, growth drivers, Strengths, weaknesses, opportunities, Threats restraining the market growth. Further, the report offers detailed visions into various growth opportunities and challenges based on various types of products, applications, end-users and countries, among others.

The Key players operating in the  Alopecia (Hair Loss Treatment) market are:

Johnson and Johnson, Alpecin, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck & Co., and Inc.

Report Scope:

This report gives a complete view of the  Alopecia (Hair Loss Treatment) market providing knowledgeable insights to the users. The report is verified and compiled by industry experts focusing on the key information that is required by the users or clients.

The Researchers have studied Marketing, government initiatives, political environment, and social scenarios that are likely to contribute to the growth of the regional markets. Analysis of various regional market trends, qualitative and quantitative data corresponding the market size for the years 2018 and 2019, estimates for 2020, and growth forecast for the period from 2021 to 2027.

Attractive investment propositions in the  Alopecia (Hair Loss Treatment) market based on various segments such as product type, application, end-user etc. Key driving and success factors along with agony points in the form of growth drivers and restraints governing the market outlook along with future trend analysis.

Comprehensive company profiles giving visions into their supply chain analysis, Financial strategies, revenue information, product offerings, Market and Sales strategies and recent market activities.
Information on industry value chain analysis of the  Alopecia (Hair Loss Treatment) market providing an investigative study of key stakeholders involved, which could expedite market participants in formulating appropriate strategies. Competitive view of the  Alopecia (Hair Loss Treatment) and market share analysis based on company’s performance and customer reach. Insights on Competition, Customer and Market for making informed decisions.

Report Overview:

This project study is conducted with a global point of view in terms of the various segments in the  Alopecia (Hair Loss Treatment) market. Market sizing and forecast have been conducted for 5 geographic regions viz. Europe, Middle East and Africa (MEA), North America, Latin America and Asia-Pacific along with the below-mentioned list of countries present in it. Market sizing data is covered in US$ with historic data for the years 2018 and 2019, 2020 as the base year along with estimations and forecasts for the period from 2021 to 2028.

The ongoing COVID-19 pandemic has had a significant impact on overall international trade and businesses. This report provides the latest insights into the  Alopecia (Hair Loss Treatment) market factoring in various effects of the industry disruptions and halts caused by COVID-19.

Market Segmentation:

Alopecia (Hair Loss Treatment) market, by Type:
Type 1
Type 2
Other Types

Alopecia (Hair Loss Treatment) market, by Application:

Application 1
Application 2
Other Applications

Alopecia (Hair Loss Treatment) market, by Geography:

North America
U.S.
Canada
Mexico

Europe
UK
Germany
France
Italy
Spain
Rest of Europe

Asia Pacific
China
Japan
India
Korea
SEA countries
Rest of Asia Pacific

Latin America
Brazil
Argentina
Peru
Rest of Latin America

The Middle East and Africa (MEA)
GCC Countries
South Africa
UAE
Saudi Arabia
Rest of MEA

FAQs –

How big is the  Alopecia (Hair Loss Treatment) market
What is the  Alopecia (Hair Loss Treatment) market growth
Which are the regions for investments
What is the COVID 19 analysis of the Alopecia (Hair Loss Treatment) market
Which are the preferred low-cost/best cost sourcing countries
Which are the key suppliers for the  Alopecia (Hair Loss Treatment) market

Global and Japan Alopecia (Hair Loss Treatment) Market Insights, Forecast to 2027

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

/in /by

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia

/in /by

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market exposition comprehensive information that help to build business strategists during the forecast 2021-2027.

Which provides an exhaustive analysis of key market trends & dynamics along with market estimates & forecasts covering major geographies/countries on the basis of historical data. Considering Platelet Rich Plasma and Stem Cell Alopecia Treatment revolutions of the cat1 industry which is major factors of growth.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research sources which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Self-Adhesive Labels includes major supplies & Independent Consultants among others.

The report used two methodologies FPNV Positioning Matrix and the Competitive Strategic Window to assess the figures for all segments and competitive marketplace in terms of product satisfaction and business strategy they follow to sustain in the market.

Pharmaceuticals and Healthcare Development

– India has reached out to top American pharma companies seeking investment in the country’s pharmaceutical and medical devices sector
– The Serum Institute of India will invest 240 million pounds in the UK
– The annual change in WPI notified by the government works out to 0.5% for 2020, the drug prices regulator National Pharmaceutical Pricing Authority said.

Market Segmentation

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is segmented on the basis of type, application, end-use industry, and region & country.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Type

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment type, the market is divided into type Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia. Platelet Rich Plasma and Stem Cell Alopecia Treatment market’s sub-segment is expected to hold the largest market share during the forecast period. Increased demand for high-quality industrial valves in the Pharmaceuticals and Healthcare and other industries.

Also to mitigate the risk of contamination is driving the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment at present. The growing concern about the market and industry is expected to boost the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in Pharmaceuticals and Healthcare.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Application

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment application, the market is divided into Hospital, Dermatology Clinic, Other. Platelet Rich Plasma and Stem Cell Alopecia Treatment application valves are one of the most basic and indispensable components of today’s modern technological society. A market segment is expected to hold the largest market share in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market.

Global Market Scope and Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size

The scope of the report is to provide a 360-degree view of the market by assessing the entire value chain and analyzing the key Platelet Rich Plasma and Stem Cell Alopecia Treatment market trends from 2021 to 2027 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Country Level Analysis

Most of the countries are estimated to emerge as the fastest growing region and hold the largest market share in the global industrial Platelet Rich Plasma and Stem Cell Alopecia Treatment market, mainly due to Growing industry trends of present situations, which cannot be ignored. Geographically, regional insights have been segmented on the basis of North America, Europe, Asia Pacific, South America and The Middle East And Africa region.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment market players identified in the report are listed below

Kerastem, Stemcell Technologies, Eclipse, Glofinn Oy., Regen Lab SA, Histogen, RepliCel Life Sciences

Market

Some of the other major highlights of the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment report include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter’s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market during the forecast period.

COVID-19 Impact Analysis

– The COVID-19 pandemic had a significant impact on the on-trade segment and Industry.
– Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation.
– The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry is expected to stabilize after 2021.
– The liquor industry was not impacted severely due to the pandemic.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Trends

– The report identifies, determines, and forecasts the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
– Industry to Industry Holds Largest Share in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market
– It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
– Demand from Regional / geographical is Expected to Drive the Growth
– Rising Adoption of Market Segments in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Growth
– North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
– It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Platelet

Rich Plasma and Stem Cell Alopecia Treatment Market.

Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market, years considered, and study objectives. Additionally, it touches on the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth are segmented on the basis of market type, application, end-user and region.

Based on Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Based on Application

Hospital
Dermatology Clinic
Other

Regions Covered

Americas
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Chile
Colombia
Rest Of Latin America

Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Sweden
Rest of Europe

Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Indonesia
Malaysia
Thailand
Philippines,
Vietnam
Rest of Asia-Pacific

The Middle East And Africa
Saudi Arabia
United Arab Emirates
South Africa
Iran
Turkey
Morocco
Nigeria
Algeria
Cameroon
Chad
Congo
Egypt
Kuwait
Rest of LAMEA

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Source

Recent Posts

Celluma RESTORE for Hair Loss

Celluma RESTORE for Hair Loss

/in /by

BioPhotas Announces Celluma RESTORE for Hair Loss

BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced today a major product line extension to the Company’s award-winning Celluma SERIES of Light Therapy Devices.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions. This is the 14th model in the Celluma SERIES.

The all-in-one Celluma RESTORE is the first LED device FDA-cleared for over-the-counter (OTC) use to treat three common concerns of the mature individual in a single device: hair loss, ageing skin, and general pain conditions.

Commenting on the latest addition to the product line, BioPhotas President and Chief Executive Officer Patrick Johnson said, “It’s great to add a Hair Restoration indication-for-use to our long list of treatment clearances from the FDA. Providing a single device that treats whole body aches and pains, fine lines and wrinkles, and hair loss on the scalp is the ultimate baby-boomer anti-ageing device.

Now the mature individual interested in feeling and looking great, and retaining their youthful appearance, can have a device at home that meets all of their rejuvenating needs.” The Celluma RESTORE is targeted directly at the multi-billion-dollar global health and wellness market, specifically, the non-invasive hair restoration segment of the medical aesthetics industry.

The Celluma RESTORE is non-toxic, non-invasive, and painless. The device is versatile, convenient, and easy-to-use in both a clinical setting or at home. Celluma’s patented, the shape-taking design permits customized placement over the head to effectively deliver light energy and promote hair regrowth.

Additionally, the Celluma RESTORE can be placed anywhere on the body to reduce pain and improve skin health. Measuring 16″ x 8″ overall with a treatment area of 14″ x 6″, the Celluma RESTORE can be stored flat in a drawer for convenience and easy access.

Commenting further on the announcement, Mr Johnson said, “Having just celebrated the 10th anniversary of BioPhotas, it is only appropriate that we receive our 10th indication-for-use clearance from the FDA. The Celluma SERIES now has more regulatory credentials than any other LED device in the world and is legally registered for sale in 78 countries around the globe.

We anticipate that the new RESTORE will be available to our U.S. customers in mid-August. The new device is already slated for MDR Tech File review later this summer and should be available in the E.U. and U.K. in the 4th quarter.”

The Celluma SERIES has also continued its winning ways by adding five new industry awards in the first half of 2021. Celluma Light Therapy was recognized by Les Nouvelles Esthetiques & Spa Magazine with two Best Product awards. Dermascope Magazine also recognized Celluma devices with two Aesthetician’s Choice Awards. And the readers of Skin Deep Magazine awarded Celluma the Reader’s Choice award for Favorite LED Device, making the Celluma SERIES the most award-winning LED device with more than 40 international awards.

Visit www.celluma.com to see the complete line of Celluma devices.

About BioPhotas, Inc.

In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions.

BioPhotas Announces Celluma RESTORE for Hair Loss

Source

Recent Posts

Hair Loss Treatments Market

Hair Loss Treatments Market

/in /by

Topical Hair Loss Treatments Market Insights 2020, Global and Chinese Analysis and Forecast to 2024

Topical Hair Loss Treatments Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Topical Hair Loss Treatments industry with a focus on the Chinese market. The report provides key statistics on the market status of the Topical Hair Loss Treatments manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Overall, the report provides an in-depth insight into the 2014-2024 global and Chinese Topical Hair Loss Treatments market covering all important parameters.

The key points of the report:

1.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.

2.The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2014-2019 market shares for each company.

3.Through the statistical analysis, the report depicts the global and Chinese total market of the Topical Hair Loss Treatments industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

5.The report then estimates the 2019-2024 market development trends of the Topical Hair Loss Treatments industry. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out.

6.The report makes some important proposals for a new project of Topical Hair Loss Treatments Industry before evaluating its feasibility.

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For the competitor segment, the report includes global key players of Topical Hair Loss Treatments as well as some small players. At least 11 companies are included:

* J&J
* Taisho Pharma
* Costco Wholesale
* Wal-Mart
* P&G
* Zhejiang Wansheng Pharma

For a complete companies list, please ask for sample pages. The information for each competitor includes:

* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For the product type segment, this report listed the main product type of Topical Hair Loss Treatments market in global and china.

* Minoxidil Solution
* Herbal Extract Treatment
* Other

For the end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.

* Male
* Female
* Both

Reasons to Purchase this Report: * Estimates 2019-2024 Topical Hair Loss Treatments market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
* Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format. Any special requirements about this report, please let us know and we can provide a custom report.

Topical Hair Loss Treatments Market Insights 2020, Global and Chinese Analysis and Forecast to 2024

Source

Recent Posts

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market

/in /by

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Androgenic Alopecia Drug Market Size and Forecasts 2021 to 2027

The Global Androgenic Alopecia Drug Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.

Global Androgenic Alopecia Drug Market Size, Trends, Growth, Competitive Landscape and Key Regional Analysis to 2027” offers broad information and understanding of the Androgenic Alopecia Drug markets. The report analyses the Androgenic Alopecia Drug market for the historical (2016–2020) and forecast (2021–2027) periods. The report includes drivers, restraints and opportunities influencing the market, market size analysis with respect to revenue.

The report also provides a snapshot of the competitive landscape of the key players operating in the market along with the percentage market share of the top players. The report has a section on the impact of COVID-19 on the Androgenic Alopecia Drug market at the global and country levels.

This analysis includes demand & supply-side implications of the Androgenic Alopecia Drug market in 2019. The report is built using data and information sourced from primary & secondary research, proprietary databases paid database among others.

Androgenic Alopecia Drug Market Snapshot

Scope of the Androgenic Alopecia Drug Market Report:

This report provides an in-depth analysis of the Global Androgenic Alopecia Drug Market. The market estimates and forecasts provided in the research report are the results of in-depth secondary research coupled with primary interviews and in-house expert opinions. These market estimates and forecasts have been considered by reviewing the impact of various political, social, and economic factors along with the current market scenarios affecting the Androgenic Alopecia Drug market growth

Along with the Androgenic Alopecia Drug market summary, which includes the market dynamics comprising of drivers, restraints, and opportunities the chapter also includes a Porter’s Five Forces analysis which explains: the threat of new entrants, buyers bargaining power, bargaining power of supplier, the threat of substitutes, and competitive rivalry in the Global Androgenic Alopecia Drug Market. Furthermore, the supply chain analysis explains the various participants, such as raw material suppliers, system integrators, distributors, intermediaries and end-users within the ecosystem of the Androgenic Alopecia Drug market. It provides vendor landscape at the global level and summary of the key upcoming projects/ products

Segments Covered in the Androgenic Alopecia Drug Market Report:

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2016 to 2027.

Global Androgenic Alopecia Drug Market, By Product

  • RK-023
  • Refagro
  • RCH-01
  • SM-04554
  • HYG-440
  • Others

Global Androgenic Alopecia Drug Market, By Application

  • Clinic
  • Hospital
  • Home Use

Androgenic Alopecia Drug Market Regional Overview:

The report offers in-depth analysis of the Androgenic Alopecia Drug market at the global, regional (North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa) and key country (the US, Canada, China, India, Japan, South Korea, the U.K., Germany, France, Brazil, Mexico) levels. The market estimates and forecasts for the segmentation mentioned in the study will be provided at regional and country level. The market estimates and forecast will help understand the dominant region in 2020 and will further enlighten the upcoming region that will generate major revenue in the Androgenic Alopecia Drug market.

Global Androgenic Alopecia Drug Market: Competitive Landscape

The market analysis includes a chapter solely dedicated for key players operating in the Global Androgenic Alopecia Drug Market wherein the analysis provide an insight of the business overview, financial statements, product overview, and the strategic initiatives adopted by the market players. The companies mentioned in the study can be customized according to the client’s requirements.

Global Androgenic Alopecia Drug Market, Key Players

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

Key Questions Addressed:

  • Which innovative technology trends are expected over the next seven years?
  • Which sub segment is likely to get the maximum opportunity to grow during the forecast period?
  • Which region is projected to lead with the highest market share by 2027?
  • How are companies instigating organic and inorganic strategies to gain a surge in the market share?

Global Androgenic Alopecia Drug Market: Research Methodology

The research methodology is a mix of primary research, secondary research and industry opinion leaders. Moreover, secondary research comprises of sources such as company annual reports, press releases, and research papers related to the industry. Other sources include government websites, trade journals and associations are also been reviewed for developing business growth strategies in Androgenic Alopecia Drug Market.

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Source

Recent Posts

Gene Tied to Balding

Gene Tied to Balding

/in /by

Gene Tied to Balding May Also Raise COVID Risks for Men

It’s long been known that COVID-19 is more fatal for men than women, and new research links some of that excess risk to a gene known to cause a form of hair loss in males.

A U.S. team of researchers first suspected the link when they noticed that men with a common form of hormone-sensitive hair loss, known as androgenetic alopecia, were also more prone to being hospitalized with COVID-19.

“Among hospitalized men with COVID-19, 79% presented with androgenetic alopecia compared to 31%-53% that would be expected in a similarly aged match population,” said researchers led by Dr Andy Goren, chief medical officer at Applied Biology Inc. in Irvine, Calif. They presented their findings May 6 at the virtual spring meeting of the European Academy of Dermatology and Venereology (EADV).

The researchers noted that androgenetic alopecia is caused by the activity of the androgen receptor (AR) gene, which in some men can lead to hair loss. An enzyme called TMPRSS2, the key to COVID-19 infection, is also androgen-sensitive, and might be affected by the AR gene as well, Goren’s group explained.

One key segment on the AR gene appears to affect both COVID-19 severity and the propensity of men to lose their hair due to androgenetic alopecia.

In the new study, the Irvine group conducted a genetic analysis of 65 men hospitalized with COVID-19. They found that men with certain structural differences in the AR gene were more likely to develop severe COVID-19. Speaking in a meeting press release, Goren said the AR gene aberration “could be used as a biomarker to help identify male COVID-19 patients most at risk for ICU admissions.”

He also believes that “the identification of a biomarker connected with the androgen receptor is another piece of evidence highlighting the important role of androgens [male hormones] in COVID-19 disease severity.”

Dr. Teresa Murray Amato is chair of emergency medicine at Long Island Jewish Forest Hills in New York City and has seen many severe cases of COVID-19. She wasn’t connected to the new research, but said it “did show a significant correlation between a higher number of androgen receptors and a higher incidence of ICU admissions for patients infected with COVID-19.”

Amato added, “While the study is small and the exact association is not completely understood, it may show at least one answer to why men were more likely to be admitted to ICU and have overall higher morality with COVID-19 infections.”

According to Amato, more research is needed to determine whether “medications that block androgen receptors will be useful in treating a subset of [COVID-19] patients.”

Because the findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.

Gene Tied to Balding May Also Raise COVID Risks for Men

Source

Recent Posts